ARK Investment Management Adds $9M in Recursion Pharmaceuticals, Inc. ($RXRX)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
ARK Investment Management increased its position in Recursion Pharmaceuticals, Inc. ($RXRX) by 7.76% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 40,212,769 shares of Recursion Pharmaceuticals, Inc. after buying 2,895,913 shares during the quarter. ARK Investment Management's holdings in Recursion Pharmaceuticals, Inc. were worth $126.67 million as of its most recent filing.
Recursion Pharmaceuticals, Inc. Stock Down 5.7%
Shares of Recursion Pharmaceuticals, Inc. ($RXRX) traded around $3.15 on Saturday, down 5.7% for the day.
Recursion Pharmaceuticals, Inc. Earnings
Analysts Set New Price Targets
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Get Recursion Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $RXRX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.